Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females

Thus, we found no evidence of an increased risk of VTE associated with HPV4 among 9−26-year-old females. A particular strength of this evaluation was its control for both time-invariant and contraceptive-related time-varying potential confounding.